Snapshot from Jul 25, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Cyllene Therapeutics Series C Financing
Business funding round

Cyllene Therapeutics Series C Financing

Analysis based on 6 articles · First reported Jul 07, 2026 · Last updated Jul 08, 2026

Sentiment
40
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The financing strengthens Cyllene's balance sheet to advance its lead candidate EG110A toward pivotal trials, potentially increasing its valuation. The involvement of Lamond Ventures, the corporate venture arm of Merck Group, signals strategic interest in genetic medicine platforms.

biotechnology pharmaceuticals
Event Summary

AnBogen Therapeutics, formerly EG 427, closed a €33 million Series C financing co-led by GordonMD Global Investments and Lamond Ventures, with participation from Andera Partners, France — Bpifrance, and Lamond Ventures. The company rebranded to AnBogen Therapeutics. Proceeds will advance clinical development of EG110A for neurogenic bladder conditions and expand the HERMES platform. EG110A showed sustained reductions in urinary incontinence episodes in ongoing studies. A Phase 2b/3 study is planned for 2027.

Key Actions
100 AnBogen Therapeutics closed Series C financing
80 GordonMD Global Investments co-led financing round AnBogen Therapeutics
40 Lamond Ventures co-led financing round AnBogen Therapeutics
40 Andera Partners participated in financing AnBogen Therapeutics
40 France — Bpifrance participated in financing AnBogen Therapeutics
30 AnBogen Therapeutics rebranded from EG 427
Entities Involved
priv
AnBogen Therapeutics
Cyllene raised €33M Series C, rebranded, and advanced EG110A clinical development, positioning for Phase 2b/3 study in 2027.
Importance 100.0 Sentiment 60.0
priv
GordonMD Global Investments
Co-led the financing round, selecting Cyllene as a portfolio cornerstone based on early clinical data.
Importance 80.0 Sentiment 50.0
priv
Lamond Ventures
Co-led the financing as strategic corporate venture arm of Merck Group, supporting Cyllene's HERMES platform.
Importance 80.0 Sentiment 50.0
per
Philippe Chambon
CEO of AnBogen Therapeutics, announced the financing and rebranding, highlighting clinical progress.
Importance 60.0 Sentiment 40.0
stock
Merck Group
Affiliate Lamond Ventures co-led the round, reflecting Merck's strategic interest in genetic medicine.
Importance 50.0 Sentiment 40.0
per
Craig Gordon
Founder and CEO of GordonMD, commented on Cyllene's potential for global expansion into neurological indications.
Importance 50.0 Sentiment 40.0
priv
Andera Partners
Participated as an existing investor in the Series C round.
Importance 40.0 Sentiment 30.0
govactor
France — Bpifrance
Participated through its InnoBio 3 Fund as an existing investor.
Importance 40.0 Sentiment 30.0
per
Björn Kuhl
Principal at Lamond Ventures, expressed support for Cyllene's HERMES platform and clinical milestones.
Importance 30.0 Sentiment 30.0
curr
European Union — Euro
Currency denomination of the €33 million financing; no direct impact on the euro.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.